Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
This article was originally published in The Tan Sheet
Executive Summary
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.
You may also be interested in...
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings